National Center for Biotechnology Information. PubChem Compound Summary for CID 176870, ELB. 2023. Retrieved April 16, 2023, from https://pubchem.ncbi.nlm.nih.gov/compound/ELB.

Jahangiri A, Khalilzad F, Barghi L. Dissolution improvement of binary solid dispersions of ELB prepared by one-step electrospray method. Biology Methods and Protocols. 2022;7(1): bpac001.

Article  PubMed  PubMed Central  Google Scholar 

Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, et al. Approval summary for ELB for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(18):6414–21. https://doi.org/10.1158/1078-0432.CCR-05-0790.

Article  CAS  PubMed  Google Scholar 

Jawhari D, Alswisi M, Ghannam M, Al Halman J. Bioequivalence of a new generic formulation of ELB hydrochloride 150 mg tablets versus tarceva in healthy volunteers under fasting conditions. J Bioequiv Availab. 2014;6(4):119–23.

Article  Google Scholar 

Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cellular and molecular life sciences: CMLS. 2008;65(10):1566–84. https://doi.org/10.1007/s00018-008-7440-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: recent advances. F1000Research. 2016;5:2270. https://doi.org/10.12688/f1000research.9025.1.

Article  CAS  Google Scholar 

Gruber A, Czejka M, Buchner P, Kitzmueller M, Kirchbaumer Baroian N, Dittrich C. Monitoring of ELB in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. Cancer Chemother Pharmacol. 2018;81(4):763–71. https://doi.org/10.1007/s00280-018-3545-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kletzl H, Giraudon M, Ducray PS, Abt M, Hamilton M, Lum BL. Effect of gastric pH on ELB pharmacokinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs. 2015;26(5):565–72. https://doi.org/10.1097/CAD.0000000000000212.

Article  CAS  PubMed  Google Scholar 

https://go.drugbank.com/drugs/DB00530

Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor ELB to a reactive electrophile. Drug metabolism and disposition: the biological fate of chemicals. 2010;38(7):1238–45. https://doi.org/10.1124/dmd.109.030361.

Article  CAS  PubMed  Google Scholar 

Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M. Metabolism and excretion of ELB, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34(3):420–6.

Article  CAS  PubMed  Google Scholar 

Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R. Clinical pharmacokinetics of ELB in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136–45. https://doi.org/10.1016/j.clpt.2006.04.007.

Article  CAS  PubMed  Google Scholar 

Christiansen SR, Broniscer A, Panetta JC, Stewart CF. Pharmacokinetics of ELB for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. Pharmacotherapy. 2009;29(7):858–66. https://doi.org/10.1592/phco.29.7.858.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH. Pharmacokinetics of ELB and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol. 2010;5(5):601–5.

Article  PubMed  Google Scholar 

Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with ELB, an epidermal growth factor receptor tyrosine kinase inhibitor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(15):3080–90. https://doi.org/10.1200/JCO.2004.08.189.

Article  CAS  PubMed  Google Scholar 

Carter J, Tadi P. ELB. [Updated 2022 Dec 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554484/

Yang QC, Bao J, Li C, Tan G, Wu AH, Ye L, et al. A murine model of dry eye induced by topical administration of ELB eye drops. Int J Mol Med. 2018;41(3):1427–36. https://doi.org/10.3892/ijmm.2017.3353.

Article  CAS  PubMed  Google Scholar 

Svedberg A, Vikingsson S, Vikström A, Hornstra N, Kentson M, Branden E, et al. ELB treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. Br J Clin Pharmacol. 2019;85(8):1704–9. https://doi.org/10.1111/bcp.13953.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:1–20.

Article  Google Scholar 

Paul MK, Mukhopadhyay AK. Tyrosine kinase—role and significance in Cancer. Int J Med Sci. 2004;1(2):101–15. https://doi.org/10.7150/ijms.1.101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019;9(11):668. https://doi.org/10.3390/biom9110668.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice. 2014;2014: 357027. https://doi.org/10.1155/2014/357027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17(4):536–42. https://doi.org/10.1634/theoncologist.2011-0461.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee PY, Yeoh Y, Low TY. A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis. FEBS J. 2022;290(11):2845–64.

Article  PubMed  Google Scholar 

Kim TE, Murren JR. ELB OSI/Roche/Genentech. Current opinion in investigational drugs (London, England: 2000). 2002;3(9):1385–95.

CAS  PubMed  Google Scholar 

Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, et al. Preclinical characterization of ELB, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–19. https://doi.org/10.1111/cas.13536.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Schmid-Bindert G, Zhou C. ELB in the treatment of advanced non-small cell lung cancer: an update for clinicians. Therapeutic advances in medical oncology. 2012;4(1):19–29. https://doi.org/10.1177/1758834011427927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: ELB (Tarceva®) tablets. Oncologist. 2005;10(7):461–6.

Article  CAS  PubMed  Google Scholar 

Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, et al. Maintenance ELB versus ELB at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016;102:30–7.

Article  PubMed  Google Scholar 

Rocha-Lima CM, Raez LE. ELB (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P & T: a peer-reviewed journal for formulary management. 2009;34(10):554–64.

Google Scholar